Skip to main content
SDZNY logo

Sandoz Group AG (SDZNY) Stock Price & Analysis

Sandoz Group AG (SDZNY) — price $96.15 (-0.43%), as of the Nov 19, 2026 trading session; market cap $41.7B.

Educational signal · not a buy or sell recommendation · How to read this

$96.15 −$0.42 (-0.43%) Market Cap $41.7B

Sandoz Group AG · SDZNY · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-12: Sandoz develops, manufactures and markets generic medicines and biosimilars across a broad therapeutic portfolio, alongside active pharmaceutical ingredients and finished dosage forms. The case rests on whether stronger sales and operating cash generation can translate into durable net profitability while the company funds its investment cycle and carries debt well above liquid assets.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • TEVA · Teva Pharmaceutical Industries Limited · 57 /100
  • ZTS · Zoetis Inc. · 87 /100
  • TAK · Takeda Pharmaceutical Company Limited · 73 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$96.15
Change on the day-0.43%
52-week range$65.81–$103.97
Market capitalisation$41.7B—
Price / earnings (trailing)66.24
Shares traded on the day1.4K
Beta (volatility vs the S&P 500)0.53

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $62, high $101, latest $96. $101 $62 high $101 Oct 17, 2025 Nov 19, 2026 · $96 $62Oct 17, 2025$67Oct 31, 2025$69Nov 14, 2025$71Nov 28, 2025$72Dec 12, 2025$74Dec 26, 2025$76Jan 9, 2026$81Jan 23, 2026$80Feb 6, 2026$86Feb 20, 2026$82Mar 6, 2026$77Mar 20, 2026$80Apr 2, 2026$86Apr 17, 2026$80May 1, 2026$83May 15, 2026$84May 29, 2026$84Jun 12, 2026$89Jun 26, 2026$84Jul 10, 2026$78Jul 24, 2026$90Aug 7, 2026$92Aug 21, 2026$84Sep 4, 2026$83Sep 18, 2026$83Oct 2, 2026$93Oct 16, 2026$99Oct 30, 2026$101Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sandoz Group AG (SDZNY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Moderate

Read on: Jul 13, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jul 13, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sandoz Group AG (SDZNY), and what does it report?

Short answer · as of

Sandoz is not a conventional branded-drug discovery company. Its reported sales combine generic medicines, biosimilars, active pharmaceutical ingredients and finished dosage forms sold across many therapeutic areas, so changes in portfolio mix can affect gross profit and operating profit differently from revenue.

The reporting record shows a broad pharmaceutical manufacturer whose research spending, commercial costs and manufacturing investment all sit between sales and net income. That distinction matters because recent operating improvement has not always carried through proportionately to the bottom line.

2 · Latest results

What do the latest results show for Sandoz Group AG (SDZNY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $5.77B.

The latest reported period kept revenue above the comparable prior period but below the immediately preceding period. Gross profit and operating profit followed a similar pattern, while net income and diluted earnings weakened much more sharply, showing that operating progress did not fully reach shareholders.

Operating cash flow strengthened near the top of the displayed series even as capital expenditure increased. Management separately expects currency movements to support sales and says capital expenditure should peak during the current investment cycle; those statements frame the outlook but do not explain the reported decline in net income.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$5.77B$109M$0.25 (diluted)
Q4 FY2025$5.85B$537M$1.24 (diluted)
Q2 FY2025$5.26B$376M$0.87 (diluted)
Q4 FY2024$5.32B-$150M-$0.35 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sandoz Group AG (SDZNY)?

Short answer · as of

Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Positive operating cash flow across the displayed periods, with marked recent improvement, gives Sandoz internal funding capacity during a capital-intensive phase. Cash and short-term investments have also risen substantially from the earliest displayed balances, although they retreated from the preceding period.

Debt remains far above cash and investments, leaving the company in a net-debt position. Near-term liquidity is adequate only narrowly on the current-ratio measure and weaker on the quick-ratio measure, while the modest net margin shows how much operating profit is lost before reaching net income. A reversal in cash conversion during peak investment spending would therefore put more pressure on financial flexibility.

4 · What to check next?

What should you watch next at Sandoz Group AG (SDZNY)?

Watch whether revenue resumes sequential growth, whether operating profit converts more consistently into net income, and whether operating cash flow continues to cover elevated capital expenditure. Consensus expectations call for further sales and earnings expansion, making the gap between operating performance and net earnings especially important.

Management has identified a planned Canadian approval and launch, a peak in the current capital-spending cycle and favorable currency movement as near-term markers. Progress on the launch, evidence that investment spending is cresting, and cash retention after that spending would each test a different part of the operating case.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Sandoz Group AG scored?

Sandoz combines conventional generic medicines with biosimilars and also supplies active pharmaceutical ingredients and finished dosage forms. That breadth differs from a business concentrated solely on novel branded drugs or solely on finished generic products: product mix, manufacturing execution and commercial uptake operate across several pharmaceutical formats.

The market valuation places a substantial price on earnings despite a much lower net margin than operating margin. Recent dividend increases and improving cash generation add evidence of financial progression, but the net-debt position means comparisons based only on sales growth miss an important balance-sheet difference.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Bayer AG (BAYRY) Named competitor$15.02 Nov 19, 2026$59.0B— Model unavailable
Fresenius SE & Co. KGaA (FSNUF) Named competitor$46.86 Nov 19, 2026$26.4B— Model unavailable
Haleon plc (HLNCF) Named competitor$4.52 Nov 19, 2026$39.6B— Model unavailable
JD Health International Inc. (JDHIF) Named competitor$4.79 Nov 19, 2026$15.3B— Model unavailable
Otsuka Holdings Co., Ltd. (OTSKF) Named competitor$77.50 Nov 18, 2026$40.6B— Model unavailable
Teva Pharmaceutical Industries Limited (TEVA) Same industry, near in market value$38.54 Nov 19, 2026$45.0B— 5-pillar · not comparable
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B— 5-pillar · not comparable
Takeda Pharmaceutical Company Limited (TAK) Same industry, near in market value$21.27 Nov 18, 2026$68.0B— 5-pillar · not comparable
Viatris Inc. (VTRS) Same industry, near in market value$19.88 Nov 19, 2026$22.8B— 5-pillar · not comparable
Elanco Animal Health Incorporated (ELAN) Same industry, near in market value$26.70 Nov 18, 2026$13.4B— 5-pillar · not comparable
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.85 Nov 19, 2026$12.4B— 5-pillar · not comparable
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SDZNY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SDZNY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sandoz Group AG (SDZNY)?

Read these with our analysis →

Common Questions About SDZNY (Healthcare)

The last question is answered from this page's own dated data, not from the research.

What does Sandoz sell besides generic medicines?

Sandoz also develops and markets biosimilars and provides active pharmaceutical ingredients and finished dosage forms. Its portfolio reaches across numerous therapeutic areas rather than relying on a narrowly defined disease franchise.

Are Sandoz earnings keeping pace with its recent revenue performance?

Recent revenue remained above the comparable prior period, but net income weakened sharply while operating profit held up better. The divergence makes conversion from operating profit to net earnings a key measure of progress.

Can Sandoz fund its current investment cycle from operations?

Recent operating cash flow exceeded capital expenditure, providing internal funding for the current investment phase. Continued coverage matters because management expects capital spending to crest while debt remains well above liquid assets.

How do biosimilars change the Sandoz business mix?

Biosimilars sit alongside generic medicines, ingredients and finished dosage forms, giving Sandoz exposure to more than a uniform generic-product stream. The resulting mix means revenue alone cannot show whether gross profit, operating profit and net income are improving together.

What is the SDZNY stock price today?

The last price recorded for Sandoz Group AG (SDZNY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 17 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Management outlook — dated call excerpts
  • 1. What is Sandoz Group AG (SDZNY), and what does it report?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • 2. What do the latest results show for Sandoz Group AG (SDZNY)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 2 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Sandoz Group AG (SDZNY)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Sandoz Group AG (SDZNY)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts
  • 5. How is Sandoz Group AG scored?: Business description; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Cash against market value; Recent dividends paid
  • FAQ: What does Sandoz sell besides generic medicines?: Business description
  • FAQ: Are Sandoz earnings keeping pace with its recent revenue performance?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • FAQ: Can Sandoz fund its current investment cycle from operations?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Management outlook — dated call excerpts
  • FAQ: How do biosimilars change the Sandoz business mix?: Business description; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.